Lilly's VERVE-102 Base Editor Cuts LDL Cholesterol by 62% in Phase 1b Trial, Results Published in NEJM
A single infusion of VERVE-102 reduced LDL-C by up to 62% and PCSK9 by up to 88% in a 35-patient trial, with effects sustained up to 18 months.
6 min read8 sources